Lexeo Therapeutics (NASDAQ:LXEO) Given New $25.00 Price Target at Chardan Capital

Lexeo Therapeutics (NASDAQ:LXEO) had its price target raised by Chardan Capital from $23.00 to $25.00 in a report released on Wednesday,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

LXEO has been the topic of several other reports. Leerink Partners lowered their price objective on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of Lexeo Therapeutics in a research note on Thursday, October 31st. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday, August 13th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Lexeo Therapeutics presently has a consensus rating of “Buy” and an average price target of $22.71.

Lexeo Therapeutics Trading Down 14.5 %

Lexeo Therapeutics stock opened at $6.65 on Wednesday. The company’s fifty day moving average price is $9.01 and its 200 day moving average price is $12.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 9.38. Lexeo Therapeutics has a 1 year low of $6.65 and a 1 year high of $22.33.

Insider Activity at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 5,000 shares of the company’s stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $8.10, for a total value of $40,500.00. Following the completion of the sale, the chief executive officer now owns 120,695 shares of the company’s stock, valued at approximately $977,629.50. This represents a 3.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last 90 days, insiders sold 12,500 shares of company stock valued at $113,300. 4.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Lexeo Therapeutics

Institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets increased its holdings in shares of Lexeo Therapeutics by 184.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares during the last quarter. Values First Advisors Inc. acquired a new position in shares of Lexeo Therapeutics in the 3rd quarter valued at $67,000. American International Group Inc. purchased a new position in shares of Lexeo Therapeutics during the 1st quarter worth $79,000. MetLife Investment Management LLC grew its holdings in shares of Lexeo Therapeutics by 121.5% during the 3rd quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock worth $129,000 after purchasing an additional 7,803 shares during the period. Finally, Rhumbline Advisers raised its holdings in Lexeo Therapeutics by 37.3% in the 2nd quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock valued at $214,000 after buying an additional 3,627 shares during the period. 60.67% of the stock is owned by hedge funds and other institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.